Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
advances decrease » advanced defense (Expand Search)
advanced disease » advanced stage (Expand Search), advanced breast (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
advances decrease » advanced defense (Expand Search)
advanced disease » advanced stage (Expand Search), advanced breast (Expand Search)
-
1121
Analysis of TO dynamics (post epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1122
Static spillover effects in stage 3 (post epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1123
-
1124
Dynamics of pairwise net spillovers between sectors in the first stage (pre-epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1125
Changes in total spillage during the first stage (pre-epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1126
Changes in total spillage during the third stage (post epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1127
Dynamics of pairwise net spillovers between sectors in the second stage (in- epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1128
-
1129
-
1130
Static spillovers in the first stage (pre-epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1131
Changes in total spillage during the second stage (in-epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1132
Dynamics of net spillage in the second stage (in-epidemic).
Published 2024Subjects: “…phenomenon intensified significantly…”
-
1133
-
1134
Sociodemographic and economic factors of study subjects, Ethiopia, EDHS 2005–2016 (N = 29,525).
Published 2024Subjects: -
1135
-
1136
Table 1_Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospect...
Published 2025“…Among patients with a decrease in CA19-9, the median overall survival was significantly prolonged (12.92 vs 8.89 months, P = 0.027); patients with a platelet-lymphocyte ratio (PLR) ≤ 165.62 had a significantly better mOS (12.37 vs 8.74 months, P = 0.025). …”
-
1137
-
1138
Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
1139
-
1140